GH Research Plc

As of October 31, 2025, the trend is bullish with strong daily moving averages and Bollinger Bands, but caution is advised due to mildly bearish weekly MACD and KST indicators, despite significant outperformance against the S&P 500 year-to-date.

As of October 24, 2025, GH Research Plc is in a bullish trend with moderate strength, supported by a bullish daily moving average and weekly RSI, despite some caution from weekly MACD and KST indicators.

As of October 24, 2025, GH Research Plc shows a bullish trend with strong momentum, supported by daily moving averages and monthly MACD, although caution is advised due to mixed signals in the weekly indicators.

As of October 24, 2025, GH Research Plc's technical trend is bullish, supported by strong daily moving averages and a bullish RSI, despite some caution from the weekly MACD and KST, while year-to-date, it has outperformed the S&P 500 with a return of 99.29% compared to 15.47%.

As of August 1, 2025, GH Research Plc shows a mildly bullish trend supported by daily moving averages and Bollinger Bands, despite mixed signals from MACD and Dow Theory, while outperforming the S&P 500 with year-to-date and one-year returns of 88.86% and 65.46%, respectively.

As of June 3, 2025, the technical trend is bullish, supported by daily moving averages and weekly MACD, though caution is advised due to mixed signals from monthly indicators and Dow Theory.

GH Research Plc is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $11 million and a market cap of $743.72 million. It has no dividend yield, a negative debt equity ratio, and a return on equity of -15.56%.

As of Jun 18, GH Research Plc has a market capitalization of 743.72 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a consolidated net profit of -42.10 million for the latest four quarters. As of Dec 24, the company reported shareholder's funds of 178.95 million and total assets of 188.27 million.